DUBLIN–(BUSINESS WIRE)–The “Central Nervous System Drugs Global Market Report 2019” report has been added to ResearchAndMarkets.com’s offering.
Global Central Nervous System Drugs Market Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global central nervous system drugs market.
Where is the largest and fastest growing market for the central nervous system drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Central Nervous System Drugs market global report answers all these questions and many more.
The central nervous system drugs market consists of sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that produce central nervous system drugs to treat brain and spinal cord diseases. This industry includes establishments that produce nervous system drugs, pain reducing analgesics, anti-Parkinson drugs to treat Parkinson’s disease, anticonvulsant anti-epileptics drugs to control epileptic seizures, anesthetics and other drugs such as muscle relaxants, antiemetics.
North America was the largest region in the global central nervous system drugs market, accounting for 43% of the market in 2018. Asia Pacific was the second largest region accounting for 24% of the global central nervous system drugs market. Africa was the smallest region in the global central nervous system drugs market.
Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%.
For instance, in 2017, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.
Key Topics Covered:
1. Executive Summary
2. Report Structure
3. Central Nervous System Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Central Nervous System Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Central Nervous System Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers
6. Central Nervous System Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Central Nervous System Drugs Market Trends And Strategies
8. Central Nervous System Drugs Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, Value ($ Billion)
8.2.1. Drivers Of The Market
8.2.2. Restraints On The Market
8.3. Forecast Market Growth, Value ($ Billion)
8.3.1. Drivers Of The Market
8.3.2. Restraints On The Market
9. Central Nervous System Drugs Market Regional Analysis
9.1. Global Central Nervous System Drugs Market, 2018, By Region, Value ($ Billion)
9.2. Global Central Nervous System Drugs Market, 2014 – 2022, Historic And Forecast, By Region
9.3. Global Central Nervous System Drugs Market, Growth And Market Share Comparison, By Region
10. Central Nervous System Drugs Market Segmentation
10.1. Global Central Nervous System Drugs Market, Segmentation By Type, 2014 – 2022, Value ($ Billion)
10.1.1. Nervous System Drugs
10.1.2. Analgesics
10.1.3. Anti-Parkinson drugs
10.1.4. Anesthetics
10.1.5. Anti-Epileptics
10.1.6. Other CNS drugs
11. Central Nervous System Drugs Market Metrics
11.1. Central Nervous System Drugs Market Size, Percentage Of GDP, 2014 – 2022, Global
11.2. Per Capita Average Central Nervous System Drugs Market Expenditure, 2014 – 2022, Global
Companies Mentioned
- Biogen Inc
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Pfizer Inc
- Novartis AG
For more information about this report visit https://www.researchandmarkets.com/r/k0ilos
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs